In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations"

letter to the editor. We have read with interest the article titled “Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations” by Passaro et al. 1 In their multicenter retrospective observational study on the activity of first- or second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in uncommon EGFR-mutated advanced non–small-cell lung cancer (NSCLC), 88 patients were enrolled during a 13-year period. Cohort B included 42 patients with exon 18 mutations and cohort A, 46 patients with complex mutations (co-occurring common mutations, classic with uncommon mutations or double uncommon mutations). In cohort B, 69% of the patients and in cohort A, 78.3% of the patients had received EGFR TKI as first-line treatment. In cohort B, the median progression-free survival (mPFS) was 8.3 months and the median overall survival (mOS) was 17.0 months. In contrast, in cohort A, the mPFS was 12.3 months and the mOS was 31.0 months, with, apparently, no detrimental effects resulting from the presence of exon 20 mutations in cohort A.